growth hormone-releasing hormone (GHRH) analog

---

Tesamorelin – Research Peptide (GHRH Analog)

Tesamorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH). It is designed to interact with GHRH receptors in the anterior pituitary and is commonly studied in laboratory research involving growth hormone regulatory pathways and endocrine signaling. Through activation of GHRH receptors, tesamorelin may stimulate the release of endogenous growth hormone and influence downstream insulin-like growth factor-1 (IGF-1) activity, making it of interest in studies examining growth hormone axis physiology.

A pharmaceutical formulation of tesamorelin has been approved by the U.S. Food and Drug Administration for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. The material offered here is not a pharmaceutical product and is supplied strictly for laboratory research purposes.

All products sold on this website are intended strictly for laboratory research and analytical purposes. Products are not intended for human or animal consumption and are not intended for therapeutic, diagnostic, or clinical use.

The materials offered are supplied solely for in vitro research conducted by qualified professionals in controlled laboratory environments.

None of the products sold on this website have been approved by the U.S. Food and Drug Administration (FDA) for any use outside of approved pharmaceutical formulations.

By purchasing from this website, the customer acknowledges that they are a qualified researcher or purchasing on behalf of a qualified research professional and agrees that the products will be handled and used in accordance with all applicable laws and regulations.

The purchaser assumes full responsibility for proper handling, storage, and lawful use of these materials.